Page 4 - Van Rompay News Today

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceutica...

Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV, a Novel Non-Opioid Pain Treatment, in Key European Markets Liège, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operat...

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended its existing license and distribution agreement with Pharma Bavaria International for the commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain, in South America. The ext...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV Hyloris Pharmaceuticals SAApril 28, 2021 GMT Hikma Pharmaceuticals, a leading supplier of complex, injectable hospital products in the U.S., to commercialise Maxigesic IV in the U.S. Hyloris is eligible to receive $4 million in regulatory based milestones as well as commercial milestones and a share of net profit Maxigesic I...

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with =4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan 14 commercial products expected by 2024 Conference call and Liège, Belgium - 9 March 2021 - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populati...

Mithra Logo (CNW Group/Searchlight Pharma Inc.) First E4-based product approved internationally Canadian regulatory approval is the first in the world for the novel combined oral contraceptive Nextstellis ® Approval supported by two large multinational Phase 3 studies conducted in 3,725 women Commercial launch in Canada anticipated mid-summer 2021 LIEGE, Belgium and MONTREAL, March 8, 2021 /CNW/ - Mithra and Searchlight Pharma announced today that Health Canada has approved Nextstellis ®, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV ... Hyloris PharmaceuticalsMarch 5, 2021 GMT Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets Footprint across Europe now extended to a total of 20 EU member states Maxigesic® IV offers a non-opioid alternative in post-operative...

Future Vaccines Depend on Test Subjects in Short Supply: Monkeys Veterinary techs distribute food every morning to more than 5,000 monkeys at the Tulane University National Primate Research Center outside New Orleans.Credit... Feb. 23, 2021 Mark Lewis was desperate to find monkeys. Millions of human lives, all over the world, were at stake. Mr. Lewis, the chief executive of Bioqual, was responsible for providing lab monkeys to pharmaceutical companies like Moderna and Johnson & Johnson, which n...

A global monkey shortage, resulting from the unexpected demand caused by the pandemic, has been exacerbated by a recent ban on the sale of wildlife from China.

A global monkey shortage, resulting from the unexpected demand caused by the pandemic, has been exacerbated by a recent ban on the sale of wildlife from China.